Study to Evaluate Pharmacokinetic Comparability Between AZD7442 Co-formulation (AZD8895 + AZD1061) vs AZD8895 and AZD1061 Individually in Adult Healthy Participants

Trial Identifier: D8850C00009
Sponsor: AstraZeneca
NCTID:: NCT05166421
Start Date: November 2021
Primary Completion Date: July 2023
Study Completion Date: July 2023

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description
English Version
Spanish (US) Translation

Trial Locations

Country Location
US, AL Anniston, AL, US, 36207
US, AL Cullman, AL, US, 35055
US, AZ Scottsdale, AZ, US, 85260
US, CA Chula Vista, CA, US, 91911
US, CA La Mesa, CA, US, 91942
US, CA North Hollywood, CA, US, 91606
US, California Long Beach, California, US, 90806
US, FL Edgewater, FL, US, 32132
US, FL Lake Worth, FL, US, 33462
US, Florida Orlando, Florida, US, 320919
US, ID Meridian, ID, US, 83642
US, NJ Berlin, NJ, US, 08009
US, SC Union, SC, US, 29379
US, TX Houston, TX, US, 77058